Rajat Deo,Ruth F Dubin,Yue Ren,Jianqiao Wang,Harold Feldman,Haochang Shou,Josef Coresh,Morgan E Grams,Aditya L Surapaneni,Jordana B Cohen,Mayank Kansal,Mahboob Rahman,Mirela Dobre,Jiang He,Tanika Kelly,Alan S Go,Paul L Kimmel,Ramachandran S Vasan,Mark R Segal,Hongzhe Li,Peter Ganz
{"title":"对慢性肾脏病患者继发性心血管事件风险的蛋白质组学评估","authors":"Rajat Deo,Ruth F Dubin,Yue Ren,Jianqiao Wang,Harold Feldman,Haochang Shou,Josef Coresh,Morgan E Grams,Aditya L Surapaneni,Jordana B Cohen,Mayank Kansal,Mahboob Rahman,Mirela Dobre,Jiang He,Tanika Kelly,Alan S Go,Paul L Kimmel,Ramachandran S Vasan,Mark R Segal,Hongzhe Li,Peter Ganz","doi":"10.1681/asn.0000000502","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nCardiovascular risk models have been developed primarily for incident events. Well-performing models are lacking to predict secondary cardiovascular events among people with a history of coronary heart disease, stroke, or heart failure who also have chronic kidney disease (CKD). We sought to develop a proteomics-based risk score for cardiovascular events in individuals with CKD and a history of cardiovascular disease.\r\n\r\nMETHODS\r\nWe measured 4638 plasma proteins among 1067 participants from the Chronic Renal Insufficiency Cohort (CRIC) and 536 individuals from the Atherosclerosis Risk in Communities Cohort (ARIC). All had non-dialysis-dependent CKD and coronary heart disease, heart failure, or stroke at study baseline. A proteomic risk model for secondary cardiovascular events was derived by elastic net regression in CRIC, validated in ARIC, and compared to clinical models. Biologic mechanisms of secondary events were characterized through proteomic pathway analysis.\r\n\r\nRESULTS\r\nA 16-protein risk model was superior to the Framingham risk score for secondary events, including a modified score that included estimated glomerular filtration rate (eGFR). In CRIC, the annualized area under the receiver operating characteristic (AUC) within 1 to 5 years ranged between 0.77 and 0.80 for the protein model and 0.57 and 0.72 for the clinical models. These findings were replicated in the ARIC validation cohort. Biologic pathway analysis identified pathways and proteins for cardiac remodeling and fibrosis, vascular disease, and thrombosis.\r\n\r\nCONCLUSIONS\r\nThe proteomic risk model for secondary cardiovascular events outperformed clinical models based on traditional risk factors and eGFR.","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":"76 1","pages":""},"PeriodicalIF":10.3000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proteomic Assessment of the Risk of Secondary Cardiovascular Events among Individuals with CKD.\",\"authors\":\"Rajat Deo,Ruth F Dubin,Yue Ren,Jianqiao Wang,Harold Feldman,Haochang Shou,Josef Coresh,Morgan E Grams,Aditya L Surapaneni,Jordana B Cohen,Mayank Kansal,Mahboob Rahman,Mirela Dobre,Jiang He,Tanika Kelly,Alan S Go,Paul L Kimmel,Ramachandran S Vasan,Mark R Segal,Hongzhe Li,Peter Ganz\",\"doi\":\"10.1681/asn.0000000502\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\r\\nCardiovascular risk models have been developed primarily for incident events. Well-performing models are lacking to predict secondary cardiovascular events among people with a history of coronary heart disease, stroke, or heart failure who also have chronic kidney disease (CKD). We sought to develop a proteomics-based risk score for cardiovascular events in individuals with CKD and a history of cardiovascular disease.\\r\\n\\r\\nMETHODS\\r\\nWe measured 4638 plasma proteins among 1067 participants from the Chronic Renal Insufficiency Cohort (CRIC) and 536 individuals from the Atherosclerosis Risk in Communities Cohort (ARIC). All had non-dialysis-dependent CKD and coronary heart disease, heart failure, or stroke at study baseline. A proteomic risk model for secondary cardiovascular events was derived by elastic net regression in CRIC, validated in ARIC, and compared to clinical models. Biologic mechanisms of secondary events were characterized through proteomic pathway analysis.\\r\\n\\r\\nRESULTS\\r\\nA 16-protein risk model was superior to the Framingham risk score for secondary events, including a modified score that included estimated glomerular filtration rate (eGFR). In CRIC, the annualized area under the receiver operating characteristic (AUC) within 1 to 5 years ranged between 0.77 and 0.80 for the protein model and 0.57 and 0.72 for the clinical models. These findings were replicated in the ARIC validation cohort. Biologic pathway analysis identified pathways and proteins for cardiac remodeling and fibrosis, vascular disease, and thrombosis.\\r\\n\\r\\nCONCLUSIONS\\r\\nThe proteomic risk model for secondary cardiovascular events outperformed clinical models based on traditional risk factors and eGFR.\",\"PeriodicalId\":17217,\"journal\":{\"name\":\"Journal of The American Society of Nephrology\",\"volume\":\"76 1\",\"pages\":\"\"},\"PeriodicalIF\":10.3000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of The American Society of Nephrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1681/asn.0000000502\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of The American Society of Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1681/asn.0000000502","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Proteomic Assessment of the Risk of Secondary Cardiovascular Events among Individuals with CKD.
BACKGROUND
Cardiovascular risk models have been developed primarily for incident events. Well-performing models are lacking to predict secondary cardiovascular events among people with a history of coronary heart disease, stroke, or heart failure who also have chronic kidney disease (CKD). We sought to develop a proteomics-based risk score for cardiovascular events in individuals with CKD and a history of cardiovascular disease.
METHODS
We measured 4638 plasma proteins among 1067 participants from the Chronic Renal Insufficiency Cohort (CRIC) and 536 individuals from the Atherosclerosis Risk in Communities Cohort (ARIC). All had non-dialysis-dependent CKD and coronary heart disease, heart failure, or stroke at study baseline. A proteomic risk model for secondary cardiovascular events was derived by elastic net regression in CRIC, validated in ARIC, and compared to clinical models. Biologic mechanisms of secondary events were characterized through proteomic pathway analysis.
RESULTS
A 16-protein risk model was superior to the Framingham risk score for secondary events, including a modified score that included estimated glomerular filtration rate (eGFR). In CRIC, the annualized area under the receiver operating characteristic (AUC) within 1 to 5 years ranged between 0.77 and 0.80 for the protein model and 0.57 and 0.72 for the clinical models. These findings were replicated in the ARIC validation cohort. Biologic pathway analysis identified pathways and proteins for cardiac remodeling and fibrosis, vascular disease, and thrombosis.
CONCLUSIONS
The proteomic risk model for secondary cardiovascular events outperformed clinical models based on traditional risk factors and eGFR.
期刊介绍:
The Journal of the American Society of Nephrology (JASN) stands as the preeminent kidney journal globally, offering an exceptional synthesis of cutting-edge basic research, clinical epidemiology, meta-analysis, and relevant editorial content. Representing a comprehensive resource, JASN encompasses clinical research, editorials distilling key findings, perspectives, and timely reviews.
Editorials are skillfully crafted to elucidate the essential insights of the parent article, while JASN actively encourages the submission of Letters to the Editor discussing recently published articles. The reviews featured in JASN are consistently erudite and comprehensive, providing thorough coverage of respective fields. Since its inception in July 1990, JASN has been a monthly publication.
JASN publishes original research reports and editorial content across a spectrum of basic and clinical science relevant to the broad discipline of nephrology. Topics covered include renal cell biology, developmental biology of the kidney, genetics of kidney disease, cell and transport physiology, hemodynamics and vascular regulation, mechanisms of blood pressure regulation, renal immunology, kidney pathology, pathophysiology of kidney diseases, nephrolithiasis, clinical nephrology (including dialysis and transplantation), and hypertension. Furthermore, articles addressing healthcare policy and care delivery issues relevant to nephrology are warmly welcomed.